Go Pro
NASDAQ:FENC

Adherex Technologies Q3 2025 Earnings Report

Adherex Technologies logo
$10.51 -0.50 (-4.54%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$10.51 0.00 (0.00%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adherex Technologies EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Adherex Technologies Revenue Results

Actual Revenue
$12.46 million
Expected Revenue
$13.43 million
Beat/Miss
Missed by -$971.00 thousand
YoY Revenue Growth
N/A

Adherex Technologies Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, November 13, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Adherex Technologies' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Adherex Technologies Earnings Headlines

Elon’s AI Phone is coming
Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.tc pixel
Fennec Announces Results of Annual Meeting
See More Adherex Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email.

About Adherex Technologies

Adherex Technologies (NASDAQ:FENC) was a biotechnology company that focused on developing therapies for cancer treatment and treatment-related complications. The company is now known as Fennec Pharmaceuticals Inc. and trades on the Nasdaq under the symbol FENC.

Fennec’s principal product is PEDMARK (sodium thiosulfate), a formulation designed to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children receiving cisplatin chemotherapy for localized, non-metastatic solid tumors. Cisplatin is widely used in cancer treatment but can cause permanent damage to hearing, particularly in pediatric patients.

The company’s activities are centered on the development and commercialization of PEDMARK for pediatric oncology. Fennec serves the U.S. market and has pursued regulatory and commercial opportunities in other regions. The company’s current business represents the continuation of Adherex’s oncology-focused development efforts under the Fennec Pharmaceuticals name.

View Adherex Technologies Profile